The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.
about
KASL clinical practice guidelines: management of chronic hepatitis BApplication of nucleoside analogues to liver transplant recipients with hepatitis BDiscovery of an allosteric mechanism for the regulation of HCV NS3 protein functionLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B.Management of viral hepatitis B.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Therapy of chronic hepatitis B: current challenges and opportunities.Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Mechanisms of drug resistance and novel approaches to therapy for chronic hepatitis C.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Antiviral resistance and hepatitis B therapy.Hepatitis B therapies and antiviral resistance detection and management.Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.Update on hepatitis B virus infection.Future therapy for hepatitis B virus infection.RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.Studies on hepatitis C virus resistance to inhibitors in replicon systems.Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy.A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir.Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
P2860
Q26752475-3789C7CC-4C25-450D-980A-89B3D17BE53EQ26859796-656A60B3-E716-49A0-BAE6-B88FF7F9EE1EQ27673761-F17BEBB9-5C0D-4616-B73E-B50D09CEC9F6Q33417353-49A3FFAB-4746-4204-86EE-B6C3693B14D8Q33868880-D497171B-E2F6-438E-9288-090A8F18432CQ33959006-BDCFD0C8-5A7B-44DA-99C2-5166999C16B2Q34409020-CDEEEF79-1265-4ACD-9B09-F4C096D8F775Q34996613-785B0135-23DE-45ED-9DD7-9C427FBD5DB2Q35020833-E63F95CA-574D-4EB6-AD86-31BCA09CE156Q35020850-5AA7343F-74B7-4F0B-A04B-BF5D56D237B3Q36153966-F596D60E-7D7D-4CF1-8534-F6C127FB0D55Q36573919-A7B9A969-BF49-4AEA-B867-4DD9AA044B83Q37074608-885A8190-3E56-45FB-9AC8-E4435E8BA7C7Q37229851-F9FF9102-6C92-4900-802C-1F4700B81B55Q37255008-7993EBBA-592E-4FB2-9CEA-F3BF81A438F7Q37636111-1B055E0D-8AE5-4B2C-9B8A-1EBF4972D6A2Q38074646-2F700FAD-E922-49A3-B7A4-8E5291267ACFQ38259535-F939BA11-9BCE-472F-A7B3-17F99C60E0ABQ38565056-739E37DC-55C8-4A00-A64B-3CB5DE3FE96BQ40217527-882D7393-6281-4ED8-89DD-11D192BB1C1CQ42977247-579D72C3-4645-4BF3-B424-069FB8A99D7FQ45074262-5A61BFD1-8BEE-4B7A-A7E0-417BA825C859Q45195142-77A30F1D-2229-4D49-BA3A-BD4E3184115AQ45254325-4907A615-CB0A-419D-B594-4802AFEC0FA6Q53685677-02B358AA-8515-4C78-AEA9-C3B29248613D
P2860
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The impact of drug resistance ...... erapy for chronic hepatitis B.
@en
The impact of drug resistance ...... erapy for chronic hepatitis B.
@nl
type
label
The impact of drug resistance ...... erapy for chronic hepatitis B.
@en
The impact of drug resistance ...... erapy for chronic hepatitis B.
@nl
prefLabel
The impact of drug resistance ...... erapy for chronic hepatitis B.
@en
The impact of drug resistance ...... erapy for chronic hepatitis B.
@nl
P356
P1433
P1476
The impact of drug resistance ...... erapy for chronic hepatitis B.
@en
P2093
Richman DD
P304
P356
10.1053/JHEP.2000.18194
P407
P433
P577
2000-10-01T00:00:00Z